Tafamidis is a breakthrough therapy developed to treat transthyretin amyloidosis (ATTR), a rare disease triggered by the abnormal accumulation of proteins in organs like the heart and nerves. This progressive condition, if untreated, can severely impact organ function. Amber Lifesciences, a trusted global pharmaceutical exporter, supplies premium-quality tafamidis to meet increasing worldwide demand.

What Is Tafamidis?

• Generic Name: Tafamidis
• Brand Variants:
  • Vyndaqel – Each capsule contains 20 mg of tafamidis meglumine in a soft gelatin formulation
  • Vyndamax – 61 mg capsules (tafamidis free acid, bioequivalent dose)
• Developed By: Pfizer
• Regulatory Status:
  • Received FDA approval in 2019 for managing cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM).
  • EMA Approval (2011): Authorized for early-stage hereditary polyneuropathy

Exporters of pharmaceutical products in the LATAM, like Brazil, Argentina, Peru, Ecuador regions, helping ensure the availability of this medicine worldwide.

Therapeutic Uses of Tafamidis

For ATTR-CM (Cardiomyopathy):

• Beneficial for both hereditary and age-related forms
• Slows the progression of heart failure
• Minimizes hospitalizations
• Enhances life expectancy

For ATTR-PN (Polyneuropathy):

• Approved in Europe for treating early hereditary cases
• Preserves nerve health and physical mobility

Mechanism of Action

Tafamidis functions by binding to the transthyretin (TTR) protein, helping maintain its structure and preventing the formation of harmful amyloid fibrils. This action slows disease progression and reduces damage to vital organs like the heart and nerves.

Dosage Details

• Missed Dose: Take it once remembered unless it’s time for the next dose. Do not double dose.
• Monitoring: Routine clinical check-ups are recommended for organ function evaluation.

Clinical Trial Insights

ATTR-ACT Study:

• 29% reduction in overall mortality
• 32% fewer cardiovascular hospitalizations

Polyneuropathy Studies:

• Slower progression of nerve-related symptoms
• Improved ability to perform daily tasks

These results reinforce the global need addressed by the largest exporters of pharmaceuticals, targeting cities like São Paulo, Rio de Janeiro, Brasília, Salvador, Fortaleza etc, treatment gaps.

Safety Profile & Side Effects

Common Side Effects:

• Mild stomach issues (diarrhea, discomfort)
• Cough and respiratory sensitivity
• Increased risk of UTIs

Special Considerations:

• Can deplete vitamin A – supplementation may be needed
• Occasional rise in liver enzymes
• Not advised during pregnancy due to fetal risk

Cost & Patient Support

• U.S. List Price: Over $225,000 per year (uninsured rate)
• Support Options:
  • Pfizer’s financial assistance programs are available
  • Co-pay and compassionate use programs for eligible patients
• Insurance Coverage: Often requires prior approval under Medicare Part D

Alternatives to Tafamidis

For patients needing alternative treatment options:

• Patisiran (Onpattro) and Inotersen (Tegsedi) – Target nerve-related ATTR
• Diflunisal – Lower-cost off-label option in some regions

Why Work with Amber Lifesciences?

Amber Lifesciences provides a reliable supply of tafamidis and similar rare-disease therapies backed by:

• WHO-GMP certified manufacturing partners
• Full regulatory documentation support
• International packaging and labeling standards
• Delivery to 30+ countries
• Transparent communication and after-sales service

We also export Tafamidis 200mg tablets, which are known for their consistent results and purity.

Conclusion

Tafamidis is redefining how ATTR is managed globally. Although not a cure, it offers meaningful symptom control and life extension when used consistently. Amber Lifesciences Pvt Ltd is honored to serve hospitals, clinics, and distributors by ensuring steady supply, fair pricing, and regulatory clarity.

Ready to source Tafamidis in bulk?
Connect with Amber Lifesciences for swift logistics, certified documentation, and global market support.